10 research outputs found
Polymorphs and Cocrystals of Nalidixic Acid
Only one X-ray crystal structure of the parent quinolone
antibiotic nalidixic acid is known in the published and patent literature.
A systematic search for new solid-state forms of the drug yielded
two polymorphs (forms II and III) and six cocrystals with resorcinol,
catechol, hydroquinone, pyrogallol, orcinol, and phloroglucinol. Of
these, X-ray crystal structures were determined for polymorph II and
cocrystals with resorcinol, catechol, hydroquinone, and pyrogallol,
whereas the remaining solid forms were identified by their unique
powder X-ray diffraction patterns. Nalidixic acid is intramolecularly
O–H···O hydrogen bonded in a six-member ring,
and its molecular dimers are assembled via C–H···O
synthon. The OH donors on phenolic coformers H bond with the α-keto
acid moiety of the drug as connectors and spacers. Intermolecular
drug–drug C–H···O interactions in polymorphs
are replaced by strong drug–coformer O–H···O
hydrogen bonds in cocrystals
Polymorphs and Cocrystals of Nalidixic Acid
Only one X-ray crystal structure of the parent quinolone
antibiotic nalidixic acid is known in the published and patent literature.
A systematic search for new solid-state forms of the drug yielded
two polymorphs (forms II and III) and six cocrystals with resorcinol,
catechol, hydroquinone, pyrogallol, orcinol, and phloroglucinol. Of
these, X-ray crystal structures were determined for polymorph II and
cocrystals with resorcinol, catechol, hydroquinone, and pyrogallol,
whereas the remaining solid forms were identified by their unique
powder X-ray diffraction patterns. Nalidixic acid is intramolecularly
O–H···O hydrogen bonded in a six-member ring,
and its molecular dimers are assembled via C–H···O
synthon. The OH donors on phenolic coformers H bond with the α-keto
acid moiety of the drug as connectors and spacers. Intermolecular
drug–drug C–H···O interactions in polymorphs
are replaced by strong drug–coformer O–H···O
hydrogen bonds in cocrystals
Polymorphs and Cocrystals of Nalidixic Acid
Only one X-ray crystal structure of the parent quinolone
antibiotic nalidixic acid is known in the published and patent literature.
A systematic search for new solid-state forms of the drug yielded
two polymorphs (forms II and III) and six cocrystals with resorcinol,
catechol, hydroquinone, pyrogallol, orcinol, and phloroglucinol. Of
these, X-ray crystal structures were determined for polymorph II and
cocrystals with resorcinol, catechol, hydroquinone, and pyrogallol,
whereas the remaining solid forms were identified by their unique
powder X-ray diffraction patterns. Nalidixic acid is intramolecularly
O–H···O hydrogen bonded in a six-member ring,
and its molecular dimers are assembled via C–H···O
synthon. The OH donors on phenolic coformers H bond with the α-keto
acid moiety of the drug as connectors and spacers. Intermolecular
drug–drug C–H···O interactions in polymorphs
are replaced by strong drug–coformer O–H···O
hydrogen bonds in cocrystals
Polymorphs and Cocrystals of Nalidixic Acid
Only one X-ray crystal structure of the parent quinolone
antibiotic nalidixic acid is known in the published and patent literature.
A systematic search for new solid-state forms of the drug yielded
two polymorphs (forms II and III) and six cocrystals with resorcinol,
catechol, hydroquinone, pyrogallol, orcinol, and phloroglucinol. Of
these, X-ray crystal structures were determined for polymorph II and
cocrystals with resorcinol, catechol, hydroquinone, and pyrogallol,
whereas the remaining solid forms were identified by their unique
powder X-ray diffraction patterns. Nalidixic acid is intramolecularly
O–H···O hydrogen bonded in a six-member ring,
and its molecular dimers are assembled via C–H···O
synthon. The OH donors on phenolic coformers H bond with the α-keto
acid moiety of the drug as connectors and spacers. Intermolecular
drug–drug C–H···O interactions in polymorphs
are replaced by strong drug–coformer O–H···O
hydrogen bonds in cocrystals
Polymorphs and Cocrystals of Nalidixic Acid
Only one X-ray crystal structure of the parent quinolone
antibiotic nalidixic acid is known in the published and patent literature.
A systematic search for new solid-state forms of the drug yielded
two polymorphs (forms II and III) and six cocrystals with resorcinol,
catechol, hydroquinone, pyrogallol, orcinol, and phloroglucinol. Of
these, X-ray crystal structures were determined for polymorph II and
cocrystals with resorcinol, catechol, hydroquinone, and pyrogallol,
whereas the remaining solid forms were identified by their unique
powder X-ray diffraction patterns. Nalidixic acid is intramolecularly
O–H···O hydrogen bonded in a six-member ring,
and its molecular dimers are assembled via C–H···O
synthon. The OH donors on phenolic coformers H bond with the α-keto
acid moiety of the drug as connectors and spacers. Intermolecular
drug–drug C–H···O interactions in polymorphs
are replaced by strong drug–coformer O–H···O
hydrogen bonds in cocrystals
Polymorphs and Cocrystals of Nalidixic Acid
Only one X-ray crystal structure of the parent quinolone
antibiotic nalidixic acid is known in the published and patent literature.
A systematic search for new solid-state forms of the drug yielded
two polymorphs (forms II and III) and six cocrystals with resorcinol,
catechol, hydroquinone, pyrogallol, orcinol, and phloroglucinol. Of
these, X-ray crystal structures were determined for polymorph II and
cocrystals with resorcinol, catechol, hydroquinone, and pyrogallol,
whereas the remaining solid forms were identified by their unique
powder X-ray diffraction patterns. Nalidixic acid is intramolecularly
O–H···O hydrogen bonded in a six-member ring,
and its molecular dimers are assembled via C–H···O
synthon. The OH donors on phenolic coformers H bond with the α-keto
acid moiety of the drug as connectors and spacers. Intermolecular
drug–drug C–H···O interactions in polymorphs
are replaced by strong drug–coformer O–H···O
hydrogen bonds in cocrystals
Development of an Efficient, Scalable Route for the Preparation of a Novel Insulin-Like Growth Factor‑1 Receptor Modulator
A chromatography-free and efficient synthesis of insulin-like
growth factor-1 receptor (IGF-1R) modulator is reported. Herein we
describe an improved synthesis for the target compound, which features
facile introduction of a novel pyrrolidinyl-pyrimidyl isoxazole <b>8</b>, via in situ sulfone displacement by fluorine. The overall
process consists of six chemical steps and five isolations, with introduction
of the expensive triheterocyclic unit <b>8</b> towards the end
of the synthesis
A Greener Approach for the Large-Scale Synthesis of 1,4,5-Trisubstituted Pyrazole, AZD8329
The
development of a convenient, safe and scalable process for <b>AZD8329</b> manufacturing is reported here. Synthesis was achieved
in a two-step telescopic process with an excellent overall yield of
75%. In the first step enamine (<b>6</b>) was synthesized with
90% yield through three chemical transformations. In the next step <b>AZD8329</b> was synthesized from the reactions of <b>6</b> and 4-hydrazinobenzoic acid hydrochloride <b>7</b> through
two chemical transformations. The process is very efficient and economical,
and <b>AZD8329</b> was manufactured in multikilogram scale.
A greener approach is demonstrated through usage of a minimum number
of solvents and energy and with process mass intensity (PMI) <60
in the manufacturing process
Exploiting the Differential Reactivities of Halogen Atoms: Development of a Scalable Route to IKK2 Inhibitor AZD3264
An
efficient and scalable synthesis of AZD3264 is described in
which the differential reactivities of various halogen atoms have
been employed. The process involves five linear chemical steps with
three isolated stages starting from commercially available fragments
Development of a Safe, Scalable Process for the Preparation of an Oxaisoxazolidinone
This
report describes the development and scale up of the synthesis
of oxaisoxazolidinone <b>1</b>, a significant synthon in the
synthesis of the MRSA development compound AZD5847. Studies were carried
out to ensure a short-term, risk based preparation of <b>9</b> on a 5 L scale with a solid isolation procedure and a safe, long-term
manufacturing process for both <b>1</b> and <b>9</b> through
extensive hazards evaluation